Kestra said it is focused on at-home cardiac care for patients at elevated risk of sudden cardiac arrest, centered on its Cardiac Recovery System anchored by the ASSURE wearable cardioverter defibrillator. The company reported 33,000+ patients protected and 290 million+ covered lives. Kestra also cited a 1-year appropriate therapy rate of 5.4% during the ICD waiting period, and said 73% of sudden cardiac arrests occur at home or a residence. The presentation described a USD 10 billion U.S. total addressable market estimate, including an existing USD 1 billion+ wearable cardioverter defibrillator market. Kestra reported revenue of USD 93 million for FY25 and issued FY26 revenue guidance of USD 59.8 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kestra Medical Technologies Ltd. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.